MARKET

INCY

INCY

Incyte Corp
NASDAQ
82.54
-1.54
-1.83%
After Hours: 81.21 -1.33 -1.61% 16:42 12/06 EST
OPEN
84.02
PREV CLOSE
84.08
HIGH
84.16
LOW
82.24
VOLUME
2.02M
TURNOVER
0
52 WEEK HIGH
84.86
52 WEEK LOW
64.32
MARKET CAP
18.36B
P/E (TTM)
20.97
1D
5D
1M
3M
1Y
5Y
Syndax Pharmaceuticals And Incyte Announce Publication Of Axatilimab Phase 1/2 Data In Patients With Chronic Graft-Versus-Host Disease In Journal of Clinical Oncology
Benzinga · 1d ago
BRIEF-Incyte And CMS Announce Collaboration And License Agreement For Ruxolitinib Cream In Greater China And Southeast Asia
Reuters · 4d ago
Incyte, CMS Aesthetics Sign License Deal for Ruxolitinib Cream in Greater China, Southeast Asia
Incyte, CMS Aesthetics Sign License Deal for Ruxolitinib Cream in Greater China, Southeast Asia
MT Newswires · 4d ago
Incyte (INCY) Up 3.3% Since Last Earnings Report: Can It Continue?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 5d ago
Incyte (INCY) Outperforms YTD: Will the Momentum Continue?
Incyte (INCY) outperforms the biotech industry in the year so far and the momentum should continue in 2023 as well.
Zacks · 11/25 14:45
Incyte, Mirati team up for trial of combo therapy for solid tumors
Seekingalpha · 11/07 14:28
BRIEF-Incyte, Mirati Therapeutics Enter Into Clinical Trial Collaboration And Supply Agreement
Reuters · 11/07 14:19
Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration And Supply Agreement To Evaluate INCB99280 And Adagrasib In Patients With KRASG12C-Mutated Solid Tumors
Benzinga · 11/07 13:18
More
About INCY
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland, and Japanese office in Tokyo and Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream.

Webull offers kinds of Incyte Corporation stock information, including NASDAQ:INCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INCY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INCY stock methods without spending real money on the virtual paper trading platform.